It could be time to consider adjuvant therapy
Based on your answers, here is information on some treatment options for when cancer cells remain after treatment and surgery.
Quick Links
Prepare for a conversation with your doctor
Below are some starter questions to begin a conversation with your doctor or care team:
- What can I expect during treatment?
- How does targeted treatment differ from chemotherapy?
- How long will I be on treatment?
- What are some of the side effects I could experience during treatment?

After surgery, HER2-targeted treatment may be recommended to help kill remaining cancer cells
If you have residual disease, your doctor may recommend:
A study compared KADCYLA to Herceptin
Who was in the study?
1,486 people with certain types of HER2+ early breast cancer who:
- Received neoadjuvant treatment including a taxane and trastuzumab (Herceptin)
- Had surgery
- Had residual disease after surgery and treatment
What was the goal of the study?
To find out which adjuvant treatment, KADCYLA or Herceptin, was better at keeping people cancer-free.
What were the results?
KADCYLA significantly lowered the chance of cancer coming back compared to Herceptin, according to a comparison study.
88% of people who received KADCYLA after surgery were still cancer-free 3 years after the study was started.

77% of people who received Herceptin were still cancer-free 3 years after the study was started.
The chance of cancer coming back was lowered by 50% for people who received KADCYLA compared to people who received Herceptin.

At the time of this data review, it was too early in the study to determine if people lived longer with KADCYLA. However, people in the study will continue to be followed and evaluated.
What are the most serious side effects of KADCYLA?
- KADCYLA can cause severe liver problems that can be life-threatening.
- KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).
- Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects.
What are other possible serious side effects of KADCYLA?
- Lung problems
- Infusion-related reactions
- Serious bleeding
- Low platelet count
- Nerve damage
- Skin reactions at the infusion site
See additional Important Safety Information below.
Dosing schedule for KADCYLA
The dosing schedule is organized by cycle. Each cycle is 3 weeks long.

KADCYLA treatment is 14 cycles in total (42 weeks) unless the cancer comes back sooner or side effects require the treatment to stop.
Keep in mind that this site is for educational purposes only and that the options here are just some of the treatments you may be eligible for. Your primary sources of information should always be your doctor and the professionals who make up your care team. Only they can give you medical advice about your disease and treatment.